Novo Nordisk (NVO)
(Delayed Data from NYSE)
$127.51 USD
-7.37 (-5.46%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $127.94 +0.43 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Novo Nordisk AS falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 12,150.77 | 7,862.34 | 7,598.14 | 6,455.54 | 5,838.76 |
Depreciation/Amortization & Depletion | 1,366.77 | 1,042.46 | 958.58 | 881.36 | 848.58 |
Net Change from Assets/Liabilities | 2,903.71 | -755.58 | -1,377.17 | -666.88 | 364.26 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -607.81 | 3,021.18 | 1,570.95 | 1,288.87 | -38.97 |
Net Cash From Operating Activities | 15,813.44 | 11,170.40 | 8,750.50 | 7,958.89 | 7,012.62 |
Property & Equipment | -3,747.03 | -1,719.87 | -1,007.90 | -891.32 | -1,338.31 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -1,001.82 | -2,908.83 | 0.00 | -0.45 |
Investments | -725.42 | -437.54 | -945.21 | -58.22 | -44.82 |
Other Investing Activities | -1,900.67 | -369.15 | -166.42 | -2,487.66 | -341.62 |
Net Cash from Investing Activities | -6,373.12 | -3,528.39 | -5,028.36 | -3,437.20 | -1,725.20 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -4,344.97 | -3,410.58 | -3,094.02 | -2,582.19 | -2,298.57 |
Issuance (Repayment) of Debt | -213.01 | -340.97 | 2,461.44 | 724.94 | -111.08 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -4,612.57 | -3,582.91 | -3,423.36 | -3,082.54 | -2,909.41 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -9,170.54 | -7,334.46 | -4,055.94 | -4,939.78 | -5,319.05 |
Effect of Exchange Rate Changes | -17.28 | -33.70 | 94.03 | -69.86 | -1.05 |
Net Change In Cash & Equivalents | 252.50 | 273.85 | -239.76 | -487.94 | -32.68 |
Cash at Beginning of Period | 1,837.22 | 1,517.81 | 1,945.16 | 2,360.97 | 2,342.79 |
Cash at End of Period | 2,089.72 | 1,791.67 | 1,705.39 | 1,873.02 | 2,310.11 |
Diluted Net EPS | 2.70 | 1.73 | 1.65 | 1.38 | 1.23 |
Fiscal Year End for Novo Nordisk AS falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 6,559.45 | 3,699.26 | 12,150.77 | 9,011.12 | 5,733.26 |
Depreciation/Amortization & Depletion | 1,696.82 | 424.28 | 1,366.77 | 937.47 | 569.21 |
Net Change from Assets/Liabilities | 35.93 | -1,288.85 | 2,903.71 | -374.05 | -2,079.15 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1,060.89 | -750.57 | -607.81 | 4,931.59 | 4,307.61 |
Net Cash From Operating Activities | 9,353.09 | 2,084.12 | 15,813.44 | 14,506.12 | 8,530.93 |
Property & Equipment | -2,733.62 | -1,233.81 | -3,747.03 | -2,394.25 | -1,544.42 |
Acquisition/ Disposition of Subsidiaries | -96.39 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 886.00 | 1,887.70 | -725.42 | -980.39 | -598.43 |
Other Investing Activities | -476.62 | -77.90 | -1,900.67 | -884.91 | -184.82 |
Net Cash from Investing Activities | -2,420.63 | 575.99 | -6,373.12 | -4,259.55 | -2,327.67 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1,484.13 | -412.92 | -4,344.97 | -2,943.80 | -2,048.61 |
Issuance (Repayment) of Debt | -774.89 | -46.16 | -213.01 | -162.35 | -124.33 |
Increase (Decrease) Short-Term Debt | 4,980.23 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -4,120.78 | -4,157.90 | -4,612.57 | -4,637.98 | -2,679.04 |
Other Financing Activities | 0.00 | 775.76 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -1,399.57 | -3,841.22 | -9,170.54 | -7,744.13 | -4,851.98 |
Effect of Exchange Rate Changes | 12.41 | 6.41 | -17.28 | 13.14 | -47.92 |
Net Change In Cash & Equivalents | 5,545.31 | -1,174.70 | 252.50 | 2,515.58 | 1,303.36 |
Cash at Beginning of Period | 2,076.77 | 2,095.48 | 1,837.22 | 1,847.34 | 1,848.60 |
Cash at End of Period | 7,622.07 | 920.77 | 2,089.72 | 4,362.92 | 3,151.96 |
Diluted Net EPS | 0.65 | 0.83 | 0.71 | 0.73 | 0.63 |